-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
GSK5852
![{PARAM:[Name]}({[CAS]})](https://resource.bocsci.com/structure/1331942-30-3.gif)
| Category | Hepatitis C Virus (HCV) |
| CAS | 1331942-30-3 |
| Description | GSK5852 (GSK2485852) is an HCV NS5B polymerase inhibitor, with an IC50 value of 50 nM. GSK5852 displays antiviral activity and inhibits HCV with EC50s of 3.0 nM (genotype 1a, GT1a) and 1.7 nM (GT1b), respectively. |
Product Information
| Synonyms | 1331942-30-3|UNII-6G04C5ZNQJ|GSK-2485852|6G04C5ZNQJ|CHEMBL3121193|GSK5852|GSK-5852|[4-({[5-Cyclopropyl-2-(4-Fluorophenyl)-3-(Methylcarbamoyl)-1-Benzofuran-6-Yl](Methylsulfonyl)amino}methyl)-2-Fluorophenyl]boronic Acid|Boronic acid, B-[4-[[[5-cyclopropyl-2-(4-fluorophenyl)-3-[(methylamino)carbonyl]-6-benzofuranyl](methylsulfonyl)amino]methyl]-2-fluorophenyl]-|1PV|Boronic acid, B-(4-(((5-cyclopropyl-2-(4-fluorophenyl)-3-((methylamino)carbonyl)-6-benzofuranyl)(methylsulfonyl)amino)methyl)-2-fluorophenyl)-|SCHEMBL2294370|BDBM50495951|GSK2485852|Q27452332|[4-[[[5-cyclopropyl-2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-6-yl]-methylsulfonyl-amino]methyl]-2-fluoro-phenyl]boronic acid|B-(4-(((5-Cyclopropyl-2-(4-fluorophenyl)-3-((methylamino)carbonyl)-6-benzofuranyl)(methylsulfonyl)amino)methyl)-2-fluorophenyl)boronic acid |
| Molecular Weight | 554.37 |
| Molecular Formula | C27H25BF2N2O6S |
| Canonical SMILES | B(C1=C(C=C(C=C1)CN(C2=C(C=C3C(=C2)OC(=C3C(=O)NC)C4=CC=C(C=C4)F)C5CC5)S(=O)(=O)C)F)(O)O |
| Purity | ≥98% (HPLC) |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| Complexity | 974 |
| Exact Mass | 554.1494442 |
| In Vitro | GSK5852 (compound 87) inhibits aggregation by two mechanisms: 1) stabilizing β-flap in a closed inactive state to inhibit the initiation step of the RdRp RNA replication cycle; 2) disruption of RNA processing channels through direct spatial contact. GSK5852 is a non-nucleoside NS5B inhibitor and exhibits inhibitory effect on HCV mutant variants with EC50s of 3.2 nM (GT1a C316Y), 1.9 nM (GT1b C316N), respectively. GSK5852 displays an excellent resistance profile and shows a <5-fold potency loss across the clinically important NS5B resistance mutations. GSK5852 shows no cross-resistance against known resistance mutations in NS5B. GSK5852 (compound 3) (0-10 μM) blocks the initiation step of NS5B polymerase cycle. GSK5852 (0.6, 10 μM; 0-75 h) shows slow binding kinetics with isolated GT1b 316N protein, and with a dissociation half-life of >40 hours. GSK5852 (0.6, 10 μM; 15 min) inhibits NS5B∆21 1b 316N with an IC50 value of 130 nM. |
| Target | 50 nM (NS5B, HCV) |